Tofacitinib for hospitalized acute severe Ulcerative colitis Management (the TRIUMPH study)
PIs: Dr. Neeraj Narula, McMaster University & Dr. Tawnya Hansen, University of Manitoba
Co-Investigators
Dr. Brian Bressler, University of British Columbia
Dr. Talat Bessissow, McGill University
Dr. Farhad Peerani, University of Alberta
Purpose
The TRIUMPH study was designed to build on the existing literature by studying the efficacy of tofacitinib in a subset of ulcerative colitis patients. We are looking to determine if there is benefit from tofacitinib in the severe hospitalized population.
Study Design
To determine the effectiveness (combined and endoscopic response) and safety of tofacitinib in patients with acute severe UC who experience treatment failure to steroids or anti-TNFα/anti-integrin therapies/anti-interleukin therapies. The primary outcome of this study is to assess clinical response at day 7 among patients who receive tofacitinib.
Participating Sites
Hamilton Health Sciences Centre/McMaster University
University of Manitoba
McGill University
University of British Colombia
University of Alberta
For more information on Inclusion & Exclusion Criteria, click here.
Targets
Anticipated sample size: 26
Anticipated start date: April 2021
Anticipated end: October 2022
Additional sites are welcome! Please contact Dr. Neeraj Narula (neeraj.narula@medportal.ca) or Dr. Tawnya Hansen at (hansen.tawnya@gmail.com) for more information.